Comparative Pharmacology
Head-to-head clinical analysis: UCEPHAN versus ZERBAXA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UCEPHAN versus ZERBAXA.
UCEPHAN vs ZERBAXA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
UCEPHAN (eculizumab) is a monoclonal antibody that binds to complement protein C5, inhibiting its cleavage to C5a and C5b, thereby preventing the formation of the membrane attack complex (MAC) and terminal complement-mediated cell lysis.
Zerbaxa is a combination of ceftolozane, a cephalosporin antibiotic, and tazobactam, a beta-lactamase inhibitor. Ceftolozane inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP3, leading to cell death. Tazobactam protects ceftolozane from degradation by certain beta-lactamases.
500 mg orally every 12 hours or 250 mg orally every 8 hours.
1.5 g (ceftolozane 1 g + tazobactam 0.5 g) intravenously every 8 hours infused over 1 hour.
None Documented
None Documented
Terminal elimination half-life is 2.1 ± 0.5 hours in adults with normal renal function; prolonged to 20–50 hours in severe renal impairment (CrCl <10 mL/min).
Ceftolozane: ~3 hours; tazobactam: ~1 hour; prolonged in renal impairment.
Approximately 70–80% of an administered dose is eliminated unchanged in urine via glomerular filtration and tubular secretion; the remainder (20–30%) is eliminated via biliary/fecal routes, with <5% as metabolites.
Primarily renal excretion: ceftolozane ~95% unchanged in urine, tazobactam ~80% unchanged in urine; biliary/fecal elimination <1%.
Category C
Category C
Antibiotic, Cephalosporin
Cephalosporin/Beta-Lactamase Inhibitor Combination